Phase 2 Ovarian Cancer Trial, Recruiting NCT06303505 Sponsor: Tubulis GmbH Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Recruiting

NCT06303505
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man, or a woman who is not pregnant or breastfeeding, and you are 18 years old or older
  • Your cancer cannot be cured with currently available treatments
  • You have already tried the standard treatments available for your condition, and those options are no longer expected to help you live longer
  • Your cancer can be measured on a scan (using standard imaging guidelines), and at least one area of cancer has not been previously treated with radiation
  • You are fairly active and able to carry out daily activities with little or no limitation (confirm with trial site what this means for your specific situation)
  • Your doctor estimates you are expected to live for more than 12 weeks from causes related to your disease
  • You are willing to allow researchers to use stored tissue samples to test for certain biological markers
  • You are willing to have a detailed lung CT scan (without contrast dye) and breathing/lung function tests at the start of the trial
  • Your organs (such as kidneys, liver, and blood cells) are working well enough as determined by tests
  • Any side effects from previous treatments have mostly gone away, except for certain lasting effects like hair loss, skin colour changes, mild nerve problems from prior chemotherapy, or stable hormone-related issues being managed with medication
  • If you are able to become pregnant and are sexually active with a partner who has not been sterilised, you must agree to use at least one reliable method of contraception during the study and for a set period after finishing treatment
  • You are able to understand the study, give written consent, and follow all study-related requirements
  • You have a history of following medical instructions and are willing to cooperate with the study team
  • You are willing to sign and date the study consent form

Who may not be able to join:

  • You are pregnant, breastfeeding, or have a positive pregnancy test during the screening period
  • You have had a serious allergic reaction to the study drug or similar drugs in the same class
  • Your cancer has already stopped responding to a specific type of chemotherapy drug (called a topoisomerase-I inhibitor), meaning it got worse during treatment or within 6 months of your last dose
  • You are currently taking part in another clinical trial, or have done so within the past 28 days, or within a certain window based on the last experimental treatment you received
  • You have cancer that has spread to your spinal cord or is currently active in your brain or nervous system
  • You have had radiation therapy less than 2 weeks before joining the trial
  • You have had major surgery within 21 days before signing the consent form, unless you have fully recovered
  • You have a history of lung inflammation (not caused by infection) that needed steroid treatment, or you currently have lung inflammation
  • Your blood oxygen level while resting and breathing normal air is below 93%
  • Your lung function tests show your lungs are working below certain levels (confirm with trial site)
  • You have an abnormal heart rhythm reading on an ECG that is above a certain level (confirm with trial site)
  • You have a history of a kidney condition called nephrotic syndrome
  • You have an active eye (cornea) condition, or have had one within the past 12 months
  • You have an active, uncontrolled serious condition affecting your kidneys, liver, heart, digestive system, nervous system, or blood that your doctor believes could put you at risk during treatment
  • You have had another cancer in the past 2 years that is still being treated or has not been fully cleared, with some exceptions for certain low-risk cancers
  • You have serious uncontrolled heart conditions such as unstable chest pain, a heart attack in the last 6 months, a heart valve problem needing treatment, heart muscle inflammation, or severe heart failure
  • You are currently receiving chemotherapy, radiation therapy (except for targeted local treatment of specific lesions), immunotherapy, or steroid treatment
  • You have received a live vaccine within 30 days before starting the trial
  • You have certain active or ongoing infections, including uncontrolled hepatitis B or C, poorly managed HIV, or any other active bacterial, viral, fungal, or similar infection — some infections may be acceptable if well controlled (confirm with trial site)
  • You have a history of a serious brain infection called progressive multifocal leukoencephalopathy
  • You have a history of severe or frequently recurring infections, as judged by your doctor

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yariv Houvras, MD, PhD, Tubulis GmbH

Phone: + 49 175 800 5594

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tubulis GmbH
Registry
ClinicalTrials.gov
Start date
12 June 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇧🇪 Belgium 🇩🇪 Germany 🇷🇴 Romania 🇪🇸 Spain 🇺🇦 Ukraine 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Determination of MTD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov